Core Viewpoint - WuXi Biologics expects a revenue growth of approximately 16.7% to RMB 21.79 billion by 2025, with a gross margin increase of about 5 percentage points to 46.0% [1] Company Summary - The annual profit attributable to equity shareholders is projected to grow by approximately 45.3% to RMB 5.733 billion and by about 46.3% to RMB 4.908 billion [1] - WuXi Biologics is the largest weighted stock in the Hong Kong Stock Connect Medical ETF, accounting for over 16% of the index [1] Industry Summary - The global biotech and pharmaceutical investment and transaction activities are expected to significantly recover in 2025, driven by the flourishing development of innovative drug technology platforms [1] - The demand in the CXO industry is anticipated to fully recover, with industry prosperity likely to continue into 2026 [1] - The Hong Kong Stock Connect Medical ETF has seen a significant increase in trading volume, achieving seven consecutive days of gains as of February 11 [1]
CXO业绩强势！药明生物利润同比增长超45%，港股通医疗ETF（520510）7连阳